Literature DB >> 21270226

Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.

Argyrios Siatelis1, Dimitra P Houhoula, Joseph Papaparaskevas, Dimitrios Delakas, Athanassios Tsakris.   

Abstract

A real-time PCR targeting IS6110 was employed for the detection of Mycobacterium tuberculosis DNA in specimens collected from 10 patients treated with intravesical M. bovis bacillus Galmette-Guérin (BCG) immunotherapy for bladder malignancy. BCG DNA was detected in all urine specimens taken 24 h after the instillations, as well as in 24% of the specimens collected 7 days after the instillations; it was also detected in a single specimen taken 6 weeks after the last instillation. BCG DNA was detected in 8.3% of the blood specimens taken 1 day after instillation, and its amplification was associated with cases of self-limiting fever. These findings give indications that this real-time PCR is helpful to recognize BCG bacteremic cases, which may lead to mycobacterial infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270226      PMCID: PMC3122854          DOI: 10.1128/JCM.01595-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Molecular-beacon-based real-time PCR for detection and quantification of Mycobacterium tuberculosis DNA in clinical samples.

Authors:  Joseph Papaparaskevas; Dimitra P Houhoula; Argirios Siatelis; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

Review 2.  Long-term results of intravesical therapy for superficial bladder cancer.

Authors:  D L Lamm
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

Review 3.  Complications of bacillus Calmette-Guérin immunotherapy.

Authors:  D L Lamm
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

Review 4.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

Review 5.  Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

Authors:  Andreas Böhle; Sven Brandau
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

6.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer.

Authors:  L Bowyer; R R Hall; J Reading; M M Marsh
Journal:  Br J Urol       Date:  1995-02

9.  Rapid diagnosis of mycobacterial infections and quantitation of Mycobacterium tuberculosis load by two real-time calibrated PCR assays.

Authors:  Francesco Broccolo; Paolo Scarpellini; Giuseppe Locatelli; Anna Zingale; Anna M Brambilla; Paola Cichero; Leonardo A Sechi; Adriano Lazzarin; Paolo Lusso; Mauro S Malnati
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

10.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

Authors:  S A Brosman
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

View more
  5 in total

1.  When the Treatment is the Cause: Disseminated Bacille Calmette-Guérin Infection.

Authors:  Ana Teresa Marques Afonso; Montserrat Rodríguez Framil; Joaquín Sánchez Leira; Néstor Vázquez Agra; Federico García-Rodeja Arias
Journal:  Eur J Case Rep Intern Med       Date:  2020-06-03

2.  Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.

Authors:  Senad Bajramovic; Jasmin Alic; Edna Skopljak; Adisa Chikha; Sanela Vesnic; Velda Smajilbegovic; Damir Aganovic
Journal:  Med Arch       Date:  2020-04

3.  A case of miliary tuberculosis following transurethral surgery and prostate biopsy after intravesical Bacillus Calmette-Guerin immunotherapy.

Authors:  Yoshiaki Kurokawa; Taketo Kawai; Jimpei Miyakawa; Naohiro Makise; Yoshiyuki Akiyama; Yuta Yamada; Yusuke Sato; Daisuke Yamada; Tetsuo Ushiku; Haruki Kume
Journal:  IJU Case Rep       Date:  2021-10-03

4.  In-Cell Western Assays to Evaluate Hantaan Virus Replication as a Novel Approach to Screen Antiviral Molecules and Detect Neutralizing Antibody Titers.

Authors:  Hong-Wei Ma; Wei Ye; He-Song Chen; Tie-Jian Nie; Lin-Feng Cheng; Liang Zhang; Pei-Jun Han; Xing-An Wu; Zhi-Kai Xu; Ying-Feng Lei; Fang-Lin Zhang
Journal:  Front Cell Infect Microbiol       Date:  2017-06-20       Impact factor: 5.293

5.  The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non-muscle‑invasive Bladder Cancer.

Authors:  Satoru Muto; Yan Lu; Hisamitsu Ide; Raizo Yamaguchi; Keisuke Saito; Kousuke Kitamura; Yasuhiro Noma; Hiroki Koyasu; Hisashi Hirano; Takeshi Ashizawa; Shuji Isotani; Masayoshi Nagata; Shigeo Horie
Journal:  Eur Urol Open Sci       Date:  2021-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.